ZTS
ZTS 5.5Price and target zones价格与目标区间
What the company does公司做什么
No company description is on file. Run python .mcp/profiles.py to get one.
Investment thesis投资逻辑 from the watchlist来自关注列表
What's working
pattern-margin-intact-while-volume-falls-defers-the-damage, written 8/05 off this name, confirmed in 24h: margin held, volume fell, damage landed in the earnings base
Watch
- DOWNGRADED 8/06 from [6.5] — second FY26 guidance cut. Q2 beat EPS ($1.87 vs $1.85) and GM held 72.7%, but revenue missed and organic went −1%; adj EPS guide $6.85-7.00 → $6.15-6.25, revenue → $9.12-9.32B (−3% to −1% organic DECLINE), mgmt "assumes no near-term market stabilization." The 8/05 steelman's central pillar (+8% adj EPS growth) is falsified — the new guide is −2.5% to −4.1% vs FY25's $6.41
- Vendor
PE(fwd) 10.40is stale; true fwd 12.4x. Still: 72.7% GM, 23% ROIC, dividend covered 2.6x and safe, 1.7x leverage. FV $60-95 (central $76); spot is AT fair value. Add $58-68. Trim 14x fwd. A2026-08-05, revised 8/06
🔴 8/06 下调 —— 就在次日早晨，由 [6.5] 降至 [5.5]。等待的那道关卡给出了否定答案：第二次下调指引。 第二季度每股收益超预期（$1.87 对 $1.85），毛利率守住在 72.7%（−40 个基点）—— 但收入不及预期（$2.468B 对 $2.50B，有机增长 −1%），而且 2026 财年指引再次下调：调整后每股收益由 $6.85-7.00 降至 $6.15-6.25，收入由 $9.68-9.96B 降至 $9.12-9.32B（有机增长 −3% 至 −1%，即下滑），调整后净利润 −9% 至 −5%。管理层表示「假设近期市场不会企稳」。⚠️ 这在 24 小时内证伪了正方论证的核心支柱 —— 8/05 的上调建立在「下调后的指引仍隐含 +8.0% 调整后每股收益增长」之上；而相对 FY25 的 $6.41，新指引是 −2.5% 至 −4.1%，是下滑。✅ 但那条毛利率笔记完全说中了： pattern-margin-intact-while-volume-falls-defers-the-damage（8/05 正是基于此股写下）预测毛利率持平叠加销量下滑意味着伤害被递延、而非护城河完好 —— 而伤害正是通过盈利基数（指引 −11%）而不是毛利率这一行到来的，毛利率始终没有跌破 70%。Zoetis 仍在守价格、让销量；未破的毛利率是机制本身，而不是让人安心的理由。 🚩 关卡结果：第二次下调指引这一降级触发条件已触发；决定性的「指引重申」升级条件未达成；毛利率跌破 70% 未触发。⚠️ 供应商的 前瞻市盈率 10.40 已过时 —— 它用的是被取代的旧指引；真实前瞻为 12.4x（基于 $6.20）。仍然成立的正面因素：毛利率 72.7%、ROIC 约 23%、股息由自由现金流覆盖 2.6 倍且没有风险、杠杆 1.7x、当前价位回购具增值效应。新合理价值 $60-95（中枢 $76）—— 现价 $76.87 已处于合理价值之内，而非低于它。 在 $58-68 加仓。减持 14x 前瞻。
Competitive advantages竞争优势 from the thesis and the reports来自投资逻辑和报告
- By the §2 test — "margin compression = moat erosion" — the moat looks intact .
- Verdict on the stress-test: the moat is being taken, on three fronts, simultaneously, by one competitor, and the company is defending on a fourth front against itself.
- What survives The moat is being narrowed , not erased.
- Befrena is a new branded competitor , not a generic — it splits a duopoly, it does not commoditise the class.
- Zoetis earned monopoly rents on Apoquel for a decade.
Related companies相关公司 🟠 Pharma patent-cliff (new 8/05)
Not "healthcare" — one failure mode: an expiring monopoly against a pipeline that has to replace it in time.
Own ONE of AZN/BMY, not both — they are the same trade with opposite risk profiles. AZN is the better business, BMY the better price; on the evidence AZN wins.